Share this article on:

Transmission networks of drug resistance acquired in primary/early stage HIV infection

Brenner, Bluma Ga; Roger, Michelb; Moisi, Daniela Da; Oliveira, Maureena; Hardy, Isabelleb; Turgel, Reuvena; Charest, Huguesc; Routy, Jean-Pierred; Wainberg, Mark Aaand the Montreal PHI Cohort and HIV Prevention Study Groups

doi: 10.1097/QAD.0b013e3283121c90
Epidemiology and Social

Objectives: Population-based sequencing of primary/recent HIV infections (PHIs) can provide a framework for understanding transmission dynamics of local epidemics. In Quebec, half of PHIs represent clustered transmission events. This study ascertained the cumulative implications of clustering on onward transmission of drug resistance.

Methods: HIV-1 pol sequence datasets were available for all genotyped PHI (<6 months postseroconversion; n = 848 subtype B infections, 1997–2007). Phylogenetic analysis established clustered transmission events, based on maximum likelihood topologies having high bootstrap values (>98%) and short genetic distances. The distributions of resistance to nucleoside and nonnucleoside reverse transcriptase inhibitors and protease inhibitors in unique and clustered transmissions were ascertained.

Results: Episodic clustering was observed in half of recent/early stage infections from 1997–2008. Overall, 29 and 28% of new infections segregated into small (<5 PHI/cluster, n = 242/848) and large transmission chains (≥5 PHI/cluster, n = 239/848), averaging 2.8 ± 0.1 and 10.3 ± 1.0 PHI/cluster, respectively. The transmission of nucleoside analogue mutations and 215 resistant variants (T215C/D/I/F/N/S/Y) declined with clustering (7.9 vs. 3.4 vs. 1.2 and 5.8 vs. 1.7 vs. 1.1% for unique, small, and large clustered transmissions, respectively). In contrast, clustering was associated with the increased transmission of viruses harbouring resistance to nonnucleoside reverse transcriptase inhibitors (6.6 vs. 6.0 vs. 15.5%, respectively).

Conclusion: Clustering in early/PHI stage infection differentially affects transmission of drug resistance to different drug classes. Public health, prevention and diagnostic strategies, targeting PHI, afford a unique opportunity to curb the spread of transmitted drug resistance.

aMcGill University AIDS Centre, Jewish General Hospital, Canada

bCentre Hospitalier de l'Université de Montréal (CHUM), Canada

cInstitut national de santé publique du Québec (INSPQ), Canada

dMcGill University Health Centre, Montreal, Quebec, Canada.

Received 11 March, 2008

Revised 24 July, 2008

Accepted 24 July, 2008

Correspondence to Mark A. Wainberg, McGill AIDS Centre, Jewish General Hospital, 3755 Cote Ste Catherine Rd. Montreal, Quebec H3T 1E2, Canada. Tel: +1 514 340 8307; fax: +1 514 340 7537; e-mail:

Back to Top | Article Outline


The incidence and prevalence of HIV infections in western settings have risen in the era of highly active antiretroviral therapy (HAART), particularly among male-sex-male (MSM) populations [1–3]. Comprehensive surveillance strategies are required to monitor emerging trends in HIV transmission and assess the effectiveness of intervention strategies [4–6].

Sequence data acquired from systematic antiretroviral resistance testing programmes of primary HIV infections can provide a framework for studying transmission dynamics of local epidemics [7–14]. Accumulated HIV pol sequences allow for phylogenetic reconstruction of possible transmission events. Phylogenetic, mathematical, and epidemiological modelling can be combined to better understand factors leading to amplified transmission risk at early/acute disease stages [5–16].

In Quebec, half of early stage infections (n = 481/848) are phylogenetically linked to other primary infections, with 28% (n = 239) forming large clusters, averaging 10 primary HIV infections (PHIs) per cluster [8]. The present study was designed to evaluate the cumulative effects of clustering on forward transmission of viruses containing drug resistance mutations related to nucleoside and nonnucleoside reverse transcriptase inhibitors (NRTIs and NNRTIs), as well as protease inhibitors.

Back to Top | Article Outline


Study population

Our PHI study population was drawn from the provincial genotyping program, at either of two Quebec reference laboratories (2001–2007, n = 645) and the Quebec PHI cohort study (1997–2007, n = 249). The inclusion criterion for the genotyping programme, (PHI < 6 months), was based on laboratory requisitions completed by prescribing physicians. These patients have been infected for an average of 4.9 months [17]. The Quebec PHI cohort study provides demographic data and a serologic testing algorithm for recent seroconversions (STARHS) [2,8].

Sequence data were compiled using nonnominative identifiers and cross-identifiers to ensure confidentiality while controlling for repeat sampling. In all, 848 unique PHIs (subtype B infections) were identified. Ethics approval was obtained from individual study sites, the Laboratoire de santé publique du Québec, and the Quebec Ministry of Health committee on confidentiality and access of information.

Back to Top | Article Outline

Phylogenetic analysis

Genotyping was carried out as previously described to generate sequences spanning the protease and reverse transcriptase regions [8]. All sequences were aligned to consensus HXB2 sequences, removing gaps and cutting to identical sequence lengths using BioEdit software (Sigma-Aldrich, St Louis, Missouri, USA) [18]. Phylogenetic inter-relationships among viral sequences were estimated using neighbour joining trees and maximum likelihood methods using BioEdit and MEGA2 integrated analysis software (Sigma-Aldrich) [18,19]. Clustering was based on the robust statistical criterion of high bootstrap values (>98%) and short genetic distances [8,11,12].

Sequence data identified minor and major resistance mutations [20]. For this study, the standardized list of the HIV-1 protease and reverse transcriptase mutations established by the WHO HIV Drug Resistance Surveillance Programme (V. 07-08-05) was used for comparative analysis of the epidemiology of transmitted resistance [21]. Differences in drug resistance motifs among clustered and nonclustered primary transmissions and chronically infected groups were ascertained using contingency tests [22].

Cell culture-based phenotypic assays were used to assess drug susceptibilities of selected transmitted resistant variants [23–25]. Four G190A isolates from a large transmission cluster (n = 27), (GenBank accession numbers EU375798-EU375801), were assessed for baseline susceptibility to nevirapine (NVP), efavirenz (EFV), etravirine (ETV), and TMC-120 (dapivirine; Tibotec-Virco, Mechlin, Belgium).

Back to Top | Article Outline


Primary HIV infection study population

Between January 1998 and July 2007, sequence data were available from 848 persons, harbouring subtype B infections having clinical indications of PHI less than 6 months. Temporal changes in baseline demographics, clinical features, cluster dynamics, and transmitted resistance within our PHI cohort are summarized in Table 1. As illustrated, the extent of PHI surveillance improved in 2001 with the introduction of the provincial genotyping programme. Our cohort is representative of infections in Quebec [26].

Table 1

Table 1

Clustering represented a steady approximately 50% of PHI transmission events between 1997 and 2008. This is evident for the MSM population, that is, the male only population that excludes intravenous drug users (Table 1). The accumulation time for clusters averaged 16.5 ± 9.8 months (mean ± SD), using STARSH for the PHI cohort. However, the majority of transmissions within clusters occurred over shorter 6–12-month periods [8,10].

Overall, phylogenetic analysis identified 368 unique PHIs, 89 small clusters (<5 PHI/cluster), and 30 large clusters (≥5 PHI/cluster) representing 43.3, 28.5, and 28.1% of transmission events, respectively. There was an increase in the number and size of existent clusters between December 2005 and July 2007. The numbers of infections in small clusters and large clusters increased from 2.7 ± 0.2 to 3.4 ± 0.2 and from 8.8 ± 1.0 to 10.3 ± 1.2 PHI/cluster, respectively (mean ± SEM).

It should be noted that non-B subtype infections, including subtypes C, A/AG, AG, G, and complex recombinant forms, introduced into Quebec (n = 410) through recent immigration have been excluded from our analysis. Clustering among non-B subtypes was low (13.7%), largely restricted to heterosexual partners, and mostly involved wild-type infections.

Back to Top | Article Outline

Clustering of transmissions harbouring drug resistance

The prevalence of single drug class and multidrug resistance (MDR) in our PHI cohort was 14.9 (n = 126/848) and 2.1% (n = 18/848), respectively. No significant trend in the prevalence of transmitted resistance was obvious (Table 1). The overall incidence of PHI harbouring mutations conferring resistance to NRTIs (n = 58), NNRTIs (n = 65), and protease inhibitors (n = 42) was 6.8, 7.6, and 5.0%, respectively.

The overall frequency of drug-resistant viruses in nonclustered and clustered transmissions was similar, 14.3 and 16.5%, respectively. However, clustering had a significant impact on the relative distribution of resistance mutations for different drug classes. This is illustrated in the phylogenetic tree in Fig. 1a, which includes the 144 cases of transmitted resistance in our treatment-naive, PHI population.

Fig. 1

Fig. 1

As shown, viral variants harbouring mutations to NRTIs, including revertants at codon 215 (T215C/D/I/N/S), thymidine analogue mutations, and M184V, as well as to protease inhibitors were less frequent in clustered transmissions. In marked contrast, seven transmission clusters (clusters A–G) harboured mutations, for example, K103N, V108I, G190A, associated with resistance to NNRTIs (Fig. 1a). In addition, cluster C represents an MDR transmission network, wherein all four PHIs harboured K103N and three of the four also harboured L10I, I54V, A71V, V82A/I/T, I84I/V, and L90M. These PHIs, dating from October 2002 to May 2003, were resistant to the protease inhibitors available at that time.

Cluster A is noteworthy in that it represents the largest in our cohort, including 24 PHIs and three chronic asymptomatic patients. Clustering was episodic; six patients were infected in 2004, eight patients within a 3-month interval in 2005, and eight within a 6-month interval in 2006. All 27 patients harboured the G190A and A98S mutations. Cell-based phenotypic assays on four isolates revealed more than 100-fold NVP resistance, sensitivity to EFV and ETV, and hypersensitivity to TMC-120. This resistance profile was confirmed for these and two other isolates based on Virco Antivirogram phenotypic analysis (Virco, Mechlin, Belgium).

Back to Top | Article Outline

Effect of clustering on transmissibility of resistance

The overall frequency of viral species harbouring resistance to different classes of drugs in unique and clustered transmissions is summarized in Fig. 1b. There was a marked diminution in the incidence of viruses harbouring NRTI mutations, 215 revertants, and MDR variants in clustered transmissions (X 2 = 15.4, 15.6, and 4.8, P < 0.0001, 0.0001, and 0.05, respectively).

In contrast, clustering led to increased frequencies of NNRTI resistance in large clusters, compared with unique and small cluster transmissions (X 2 = 4.8 and 11.4, P < 0.05 and 0.001, respectively). Such forward transmission of NNRTI resistance in clusters was independent of the G190A mutation (Fig. 1).

There appeared to be no significant impact of clustering on the incidence of viral variants harbouring mutations associated with resistance to protease inhibitors. Most protease inhibitor-transmitted resistance was restricted to infections harbouring single mutations, for example, L90M, V82I, which have limited impact on drug susceptibility and viral replicative capacity. The transmission of complex protease inhibitor mutational patterns, conferring measurable phenotypic resistance, was lower in clustered transmissions (X 2 = 5.2, P < 0.05) (Fig. 1a).

Back to Top | Article Outline


Our findings are consistent with those of other studies [6–8,16] showing that early/PHI infections play a key role in the spread of HIV. Our new study provides additional data that confirm that clustering of early/recent infections in Quebec may contribute to approximately 50% of transmissions [8]. High rates of clustering in our cohort reflect a concentrated MSM epidemic in which persons unaware of their HIV status may engage in high-risk behaviours [27]. Universal access to resistance testing allows for in-depth population sampling. Our results are also consistent with models that suggest that early chronic infection contributes to HIV spread [28]. Universal access to antiretroviral drugs is an obvious factor in transmission of resistant quasispecies.

The present study illustrates the potential benefits of phylogenetics in understanding factors that govern HIV transmission and the spread of drug resistance. The implications of PHI/early infection and viral fitness in transmission networks of drug resistance are underscored by the distribution of resistant drug classes in early and chronic infection [23,29–33]. The frequencies of mutations among Quebec patients failing HAART are NRTI (64%) > protease inhibitor (42%) > NNRTI (38%) [31]. The reverse order is observed in transmitted resistance, that is, NNRTI (11%/7%) > protease inhibitor (5%/5%) > NRTI (2%/8%) in clustered and nonclustered transmissions, respectively.

Viruses harbouring NRTI and MDR resistance may be replicatively unfit, creating a bottleneck for forward transmission of such variants [29,30,32]. In contrast, clustering may facilitate spread of viruses harbouring NNRTI resistance mutations. This finding is highlighted by a transmission chain of 27 G190A-containing infections and a transmission network of NNRTI/protease inhibitor dual resistant infections (n = 4). In general, NNRTI mutations do not impact on viral replicative fitness to the same extent as either NRTI or protease inhibitor mutations [29,32,33]. The elevated frequency of acquired NNRTI resistance reported here is consistent with data from other PHI cohorts [34,35]. In contrast, clustering did not impact on the frequency of transmitted drug-resistant infections in the Swiss cohort [36].

Our findings further underscore the recommendation that all newly infected persons undergo drug resistance testing [37,38]. Resistance to antiretroviral drugs is present 10–25% of the time in PHI [8,34–36]. Transmitted drug resistance persists over time, can affect disease course in drug-naive patients, and limit strategies for antiretroviral therapy [39–44]. Although MDR variants may be less replicatively fit than wild-type archival species, the generation of resistant and MDR strains that may circumvent replicative transmission barriers is of growing concern [39]. Observations of superinfection and coinfections with resistant and MDR viruses show that resistant viruses may become more virulent and transmissible over time [33,39]. Public health strategies that target early/PHI stage infection, including the introduction of rapid testing and routine genotyping, may be of significant benefit towards reducing the incidence and spread of HIV, including that of drug-resistant variants [6–8,39,44].

Back to Top | Article Outline


We thank the patients and attending staff from all centres participating in the Quebec genotyping programme and the Montreal PHI cohort studies. Members of the Quebec Genotyping Programme/Montreal HIV Prevention Study Group: INSQ (Joe Cox, Gilles Lambert, M. Couillard), R. Rousseau (Séro-Zéro), J. Flores, R. Lavoie (COCQ), G. Emond (Concordia University); J. Otis (UQAM). Members of the Quebec PHI Study Group: M. Legault (PHI cohort coordinator); R. Leblanc, R.G. Lalonde, N. Gilmore, M. Klein, J. MacLeod, G. Smith, J. Allan, C. Tsoukas, M. Potter, J. Falutz, J. Cox (McGill University Health Center); D. Rouleau, C. Tremblay, J. Bruneau, C. Fortin, A. de Pokomandy (CHUM); R. Thomas, B. Trottier, F. Asselin, M. Boissonnault, L. Charest, H. Dion, S. Lavoie, D. Legault, D. Longpré, P.J. Maziade, M.E. Morin, D. Murphy, V.K. Nguyen, R. O'Brien, S. Vézina (Clinique médicale l'Actuel); J.G. Baril, P. Côté, S. Dufresne, P. Junod, F. Laplante, D. Poirier, Y. Parent, M.A. Charron, B. Lessard, D. Tessier, É Sasseville, A. Talbot, M.S. Joyal (Clinique médicale du Quartier Latin); N. Lapointe (Hôpital Ste-Justine); A. Dascal (Jewish General Hospital); M. Munoz (CLSC Cote des Neiges).

Sponsorship: Canadian Institutes for Health Research and the Fonds de la Recherche en Santé du Québec-Réseau SIDA (FRSQ-SIDA).

Roles of authors: B.G.B. wrote the article and coordinated all aspects of this study. M.R. and M.W. direct sites for genotypic and phylogenetic analysis for the Quebec PHI cohort and provincial genotyping program, and reviewed and revised the article. D.M., I.H. and R.T. provided phylogenetic (D.M.), genotypic (D.M. and I.H.), and database (D.M. and R.T.) analysis. M.O. performed viral isolation and phenotypic analysis. H.C. and J.-P.R. are the coordinators of the HIV genotypic programme and the Quebec PHI cohort study, respectively, and also reviewed the article.

Back to Top | Article Outline


1. Boulos D, Yan P, Schanzer D, Remis RS, Archilbald CP. Estimates of HIV prevalence and incidence in Canada. Can Commun Dis Rep 2006; 32:165–174.
2. Fisher M, Pao D, Murphy G, Dean G, McElborough D, Homer G, Jarry PV. Serological testing algorithm shows rising HIV incidence in a UK cohort of men who have sex with men: 10 years application. AIDS 2007; 21:2309–2314.
3. Marcus U, Voss L, Kollan C, Hamouda O. HIV incidence increasing in MSM in Germany: factors influencing infection dynamics. Euro Surveill 2006; 11:157–160.
4. Saloman JA, Hogan DR, Stover J, Stanecki KA, Walker N, Ghys PD, Schwartlander B. Integrating HIV prevention and treatment: from slogans to impact. PloS Med 2005; 2:e16, 50–55.
5. Koopman JS, Jacquez JA, Welch GW, Simon CP, Foxman B, Pollack SM, et al. The role of early HIV infection in the spread of HIV through populations. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 14:249–258.
6. Cohen MS, Pilcher CD. Amplified HIV transmission and new approaches to HIV prevention. J Infect Dis 2005; 191:1391–1393.
7. Pillay D, Fisher M. Primary HIV Infection, phylogenetics, and antiretroviral prevention. J Infect Dis 2007; 195:924–926.
8. Brenner BG, Roger M, Routy JP, Moisi D, Ntemgwa M, Matte C, et al. High rates of forward transmission events after acute/early HIV-1 infection. J Infect Dis 2007; 195:951–959.
9. Yerly S, von Wyl V, Junier T, Ledergerber B, Boni J, Burgisser P, et al. The contribution of individuals with recent infection to the spread of HIV-1 in Switzerland: a 10-year survey [abstract 512]. In: 15th Conference on Retroviruses and Opportunistic Infections; February 2008; Boston.
10. Lewis F, Hughes GJ, Rambaut A, Pozniak A, Leigh-Brown AJ. Episodic sexual transmission of HIV revealed by molecular phylodynamics. PLoS Med 2008; 5:392–402.
11. Hue S, Clewley JP, Cane PA, Pillay D. HIV-1 pol gene variation is sufficient for reconstruction of transmissions in the era of antiretroviral therapy. AIDS 2004; 18:719–728.
12. Hue S, Clewley, Cane PA, Pillay D. Investigation of HIV-1 transmission events by phylogenetic analysis; requirement for scientific rigour. AIDS 2005; 19:440–450.
13. Grant RM, Liegler TI, Hecht FM. Clusters and trends in primary resistance in San Francisco 2001–2003. Antivir Ther 2004; 9:S104. 1.
14. Pao D, Fisher M, Hue S, Dean G, Murphy G, Cane PA, et al. Transmission of HIV-1 during primary infection: relationship to sexual risk and sexually transmitted infections. AIDS 2005; 9:85–90.
15. Wawer MJ, Gray RH, Sewankambo NK, Serwadda D, Li X, Laeyendecker O, et al. Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda. J Infect Dis 2005; 191:1403–1409.
16. Pilcher CD, Joacki G, Hoffman IF, Martinson FE, Mapanje C, Stewart PW, et al. Amplified transmission of HIV-1: comparison of HIV-1 concentrations in semen and blood during acute and chronic infection. AIDS 2007; 21:1723–1730.
17. Routy JP, Machouf N, Edwardes MD, Brenner BG, Thomas R, Trottier B, et al. Factors associated with a decrease in the prevalence of drug resistance in newly HIV-1 infected individuals in Montreal. AIDS 2004; 18:2305–2312.
18. Hall TA. BioEdit: a user-friendly biological sequence alignment editor and analysis program for Windows 95/98/NT. Nucleic Acids Symp Ser 2000; 41:95–98.
19. Kumar S, Tamura K, Jakobsen IB, Nei M. MEGA2: molecular evolutionary genetics analysis software. Bioinformatics 2001; 17:1244–1245.
20. Johnson VA, Brun-Vezinet F, Clotet B, Gunthard HF, Kuritzkes DR, Pillay D, et al. Update of the drug resistance mutations in HIV-1: Spring 2008. Top HIV Med 2007; 16:62–68.
21. Shafer RW, Rhee S-Y, Pillay D, Miller V, Sandstrom P, Schapiro JM, et al. HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance. AIDS 2007; 21:215–233.
22. Van de Vijver, Brenner B, Turner D, Sandstorm P, Dunn D, Green H, et al. A systematic approach to identify mutations that can be used in epidemiological studies on transmission of drug resistant HIV. HIV Med 2004; 5:196.
23. Salomon H, Quan Y, Brenner B, Quan Y, Rouleau D, Côté P, et al. Prevalence of HIV-1 resistant to antiretroviral drugs in 81 individuals newly infected by sexual contact or injecting drug use. AIDS 2000; 14:F17–F23.
24. Brenner B, Routy JP, Petrella M, Moisi D, Oliveira M, Detorio M, et al. Persistence and fitness of multidrug resistant human immunodeficiency virus type 1 acquired in primary infection. J Virol 2002; 76:1753–1761.
25. Loemba H, Brenner B, Parniak MA, Ma'ayan S, Spira B, Moisi D, et al. Genetic divergence of human immunodeficiency virus type 1 Ethiopian clade C reverse transcriptase (RT) and rapid development of resistance against nonnucleoside inhibitors of RT. Antimicrob Agents Chemother 2002; 46:2087–2094.
26. Lambert G, Cox J, Tremblay F, Gadoury M-A, Frigault C, Tremblay M, et al. ARGUS 2005: summary of the survey on HIV, viral hepatitis and blood-borne infections, as well as associated risk factors among Montreal men who have sex with men. Montreal Public Health Department, Institut national de santé publique du Québec and the Public Health Agency of Canada, August 2006.
27. Marks G, Crepaz N, Janssen RS. Estimating sexual transmission of HIV from persons aware and unaware that they are infected with the virus in the USA. AIDS 2006; 18:983–989.
28. Fraser C, Hollingsworth TD, Chapman R, de Wolf F, Hanage WP. Variation in HIV-1 set-point viral load: epidemiological analysis and an evolutionary hypothesis. Proc Natl Acad Sci U S A 2007; 104:17441–17446.
29. Brenner BG, Turner D, Wainberg MA. HIV-1 drug resistance: can we overcome? Exp Opin Biol Ther 2002; 2:751–761.
30. Turner D, Brenner B, Routy JP, Petrella M, Wainberg MA. Rationale for maintenance of the M184V resistance mutation in human immunodeficiency virus type 1 reverse transcriptase in treatment experienced patients. New Microbiol 2004; 27:31–39.
31. Brenner B, Wainberg MA, Roger M. Primary HIV infections vs. genotyped chronic infections in the province of Quebec. Data from the Quebec program for HIV drug resistance testing. In: HIV Strain and Primary Drug Resistance in Canada. Surveillance March 31, 2005. August 2006. pp. 32–36.
32. Turner D, Brenner B, Routy JP, Moisi D, Rosberger Z, Roger M, Wainberg MA. Diminished representation of HIV-1 variants containing select drug resistance-conferring mutations in reverse transcriptase in primary HIV infection. J Acquir Immune Defic Syndr 2004; 37:1627–1631.
33. Brenner, Routy JP, Quan Y, Moisi D, Turner D, Wainberg MA. Persistence of multidrug-resistant HIV-1 in primary infection leading to superinfection. AIDS 2004; 18:1653–1660.
34. Shet A, Berry L, Mohri H, Mehandru S, Chung C, Kim A, et al. Tracking the prevalence of transmitted antiretroviral drug-resistant HIV-1: a decade of experience. J Acquir Immune Defic Syndr 2006; 41:439–446.
35. SPREAD programme. Transmission of drug-resistant HIV-1 in Europe remains limited to single classes. AIDS 2008; 22:625–635.
36. Yerly S, von Wyl V, Ledergerber B, Boni J, Shupbach J, Burgisser P, et al. Transmission of HIV-1 drug resistance in Switzerland: a 10-year molecular epidemiology survey. AIDS 2007; 21:2223–2229.
37. Hirsch MS, Gunthard HF, Schapiro JM, Brun-Vézinat F, Clotet B, Hammer SM, et al. Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. Clin Infect Med 2008; 47:266–285.
38. Smith D, Moini N, Pesano R, Cachay F, Aiem H, Lie Y, et al. Clinical utility of HIV standard genotyping among antiretroviral-naive individuals with unknown duration of infection. Clin Infect Dis 2007; 44:456–458.
39. Shet A, Markowitz M. Transmitted multidrug resistant HIV-1: new and investigational therapeutic approaches. Curr Opin Investig Drugs 2006; 7:709–720.
40. Chaix ML, Desquilbet L, Descamps D, Costagliola D, Deveau C, Galimand J, et al. Response to HAART in French patients with resistant HIV-1 treated at primary infection: ANRS Resistance Network. Antivir Ther 2007; 12:1305–1310.
41. Fox J, Dustan S, McClure M, Weber J, Fidler S. Transmitted drug-resistant HIV-1 in primary HIV-1 infection; incidence, evolution and impact on response to antiretroviral therapy. HIV Med 2006; 7:477–483.
42. Pillay D, Bhaskaran K, Jurriaans S, Prins M, Masqualier B, Dabis F, et al. The impact of transmitted drug resistance on the natural history of HIV infection and response to first-line therapy. AIDS 2006; 20:21–28.
43. Smith DM, Wong JK, Shao H, Hightower GK, Mai SH, Moreno JM, et al. Long-term persistence of transmitted HIV drug resistance in male genital tract secretions: implications for secondary transmission. J Infect Dis 2007; 196:356–360.
44. Ghosn J, Pellegrin I, Goujard C, Deveau C, Viard JP, Galimand J, et al. HIV-1 resistant strains acquired at the time of primary infection massively fuel the cellular reservoir and persist for lengthy periods of time. AIDS 2006; 20:159–170.

clusters; drug resistance; mutations; nonnucleoside reverse transcriptase inhibitors; pol sequencing; transmission

© 2008 Lippincott Williams & Wilkins, Inc.